Geron’s Imetelstat Headed To US FDA Advisory Committee For MDS

Geron’s telomerase inhibitor will also get standard review for transfusion-dependent anemia in adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS), suggesting FDA reviewers may be less bullish on imetelstat’s clinical data than analysts have been.